Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1124)
•••
Comment by Pandoraon Jan 08, 2021 7:35pm
213 Views
Post# 32259799

RE:RE:Don Haut

RE:RE:Don Haut
Just an observation but it seems that Stockhouse is not receiving the Antibe news releases over the past two months. The last item shown under the "news" link above is from November 10. According to the Antibe web site there have been 5 additional releases in 2020 and 1 release thus far in 2021 i.e. the one concerning Don Haut.

Not sure why they are missing the link but it seems to coincide with the week they changed to the TSX. News link originates out of Morningstar so I guess that is where the problem could be.

Under their "Canadian News Releases" header above Stockhouse does not post the daily news items from CSE listed companies but the news items still make it to the individual "news" links for each individual company. So there is a broken link somewhere. I may send a note to tech support to see if it will help.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities